1

2
Sheri Barrack, James Callaway, Michelle Mazzoni: Pegylated C-peptide. Cebix, Morrison & Foerster, April 8, 2014: US08691755 (1 worldwide citation)

The present invention relates to modified forms of C-peptide, and methods for their use. In one aspect, the modified forms of C-peptide comprise PEGylated C-peptide derivatives comprising at least one PEG group attached to the N-terminus, which exhibit superior pharmacokinetic and biological activit ...


3
Sheri Barrack, James Callaway, Michelle Mazzoni: Pegylated C-peptide. Cebix, Morrison & Foerster, January 6, 2015: US08927488

The present invention relates to modified forms of C-peptide, and methods for their use. In one aspect, the modified forms of C-peptide comprise PEGylated C-peptide derivatives comprising at least one PEG group attached to the N-terminus, which exhibit superior pharmacokinetic and biological activit ...


4
John Wahren, Sheri Barrack, James Callaway, Michelle Mazzoni, Howard Foyt, Mark Daniels: Method of treating a diabetic subject having a microvascular impairment disorder by a pegylated C-peptide. Cebix, Morrison & Foerster, February 24, 2015: US08962553

The present invention relates to PEGylated C-peptide derivatives comprising at least one PEG group attached to the N-terminus, which exhibit improved pharmacokinetic and biological activity in vivo.


5
WAHREN John, BARRACK Sheri, CALLAWAY James, MAZZONI Michelle, FOYT Howard, DANIELS Mark: [fr] PEPTIDE C PEGYLÉ, [en] PEGYLATED C-PEPTIDE. WAHREN John, BARRACK Sheri, CALLAWAY James, MAZZONI Michelle, FOYT Howard, DANIELS Mark, BENNETT Dennis A, May 23, 2013: WO/2013/075117

[en] The present invention relates to PEGylated C-peptide derivatives comprising at least one PEG group attached to the N-terminus, which exhibit improved pharmacokinetic and biological activity in vivo.


6
Sheri Barrack, James Callaway, Michelle Mazzoni: Pegylated c-peptide. Cebix, August 30, 2012: US20120220542-A1

The present invention relates to modified forms of C-peptide, and methods for their use. In one aspect, the modified forms of C-peptide comprise PEGylated C-peptide derivatives comprising at least one PEG group attached to the N-terminus, which exhibit superior pharmacokinetic and biological activit ...


7
Sheri Barrack, James Callaway, Michelle Mazzoni: PEGYLATED C-PEPTIDE. CEBIX, July 12, 2012: US20120178676-A1

The present invention relates to modified forms of C-peptide, and methods for their use. In one aspect, the modified forms of C-peptide comprise PEGylated C-peptide derivatives comprising at least one PEG group attached to the N-terminus, which exhibit superior pharmacokinetic and biological activit ...


8

9
PEGYLATED C-PEPTIDE. CEBIX, May 23, 2013: US20130130973-A1

The present invention relates to PEGylated C-peptide derivatives comprising at least one PEG group attached to the N-terminus, which exhibit improved pharmacokinetic and biological activity in vivo.


10
BARRACK Sheri, CALLAWAY James, MAZZONI Michelle: [fr] C-PEPTIDE PÉGYLÉ, [en] PEGYLATED C-PEPTIDE. CEBIX, BARRACK Sheri, CALLAWAY James, MAZZONI Michelle, McELHONE Kate, October 3, 2013: WO/2013/148579

[en] The present invention relates to modified forms of C-peptide, and methods for their use. In one aspect, the modified forms of C-peptide comprise conjugated C-peptide derivatives which exhibit superior pharmacokinetic and biological activity in vivo.